» Articles » PMID: 24577514

Elevated Tricuspid Regurgitant Jet Velocity in Subgroups of Thalassemia Patients: Insight into Pathophysiology and the Effect of Splenectomy

Overview
Journal Ann Hematol
Specialty Hematology
Date 2014 Mar 1
PMID 24577514
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A high tricuspid regurgitant jet velocity (TRV) signifies a risk for or established pulmonary hypertension (PH), which is a serious complication in thalassemia patients. The underlying pathophysiology in thalassemia subgroups and potential biomarkers for early detection and monitoring are not well defined, in particular as they relate to spleen removal. To better understand some of these unresolved aspects, we examined 76 thalassemia patients (35 non-transfused), 25 splenectomized non-thalassemia patients (15 with hereditary spherocytosis), and 12 healthy controls. An elevated TRV (>2.5 m/s) was found in 25/76 (33 %) of the patients, confined to non-transfused or those with a late start of transfusions, including patients with hemoglobin H-constant spring, a finding not previously described. These non or late-transfused patients (76 % splenectomized) had significantly increased platelet activation (sCD40L), high platelet count, endothelial activation (endothelin-1), and hemolysis (LDH, plasma-free Hb), while hypercoagulable and inflammatory markers were not significantly increased. The same markers were increased in the seven patients with confirmed PH on cardiac catheterization, suggesting their possible role for screening patients at risk for PH. A combination of hemolysis and absence of spleen is necessary for developing a high TRV, as neither chronic hemolysis in the non-splenectomized thalassemia patients nor splenectomy without hemolysis, in the non-thalassemia patients, resulted in an increase in TRV.

Citing Articles

Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Rai P, Joshi V, Goldberg J, Yates A, Okhomina V, Penkert R Blood Adv. 2021; 5(1):89-98.

PMID: 33570630 PMC: 7805333. DOI: 10.1182/bloodadvances.2020003197.


The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension.

Karami H, Darvishi-Khezri H, Kosaryan M, Akbarzadeh R, Dabirian M Int Med Case Rep J. 2018; 12:1-7.

PMID: 30588128 PMC: 6301293. DOI: 10.2147/IMCRJ.S180602.


HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.

Hirsch R, Sibmooh N, Fucharoen S, Friedman J Antioxid Redox Signal. 2016; 26(14):794-813.

PMID: 27650096 PMC: 5421591. DOI: 10.1089/ars.2016.6806.


Post splenectomy related pulmonary hypertension.

Palkar A, Agrawal A, Verma S, Iftikhar A, Miller E, Talwar A World J Respirol. 2016; 5(2):69-77.

PMID: 26949600 PMC: 4778975. DOI: 10.5320/wjr.v5.i2.69.


Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Morris C, Kim H, Klings E, Wood J, Porter J, Trachtenberg F Br J Haematol. 2015; 169(6):887-98.

PMID: 25907665 PMC: 4452408. DOI: 10.1111/bjh.13452.


References
1.
Barenholz Y, Rachmilewitz E, Eldor A . Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993; 44(1):63-5. DOI: 10.1002/ajh.2830440114. View

2.
Kuypers F, Larkin S, Emeis J, Allison A . Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost. 2007; 97(3):478-86. View

3.
Amer J, Fibach E . Oxidative status of platelets in normal and thalassemic blood. Thromb Haemost. 2004; 92(5):1052-9. DOI: 10.1160/TH04-04-0234. View

4.
Goldfarb A, Grisaru D, Gimmon Z, Okon E, Lebensart P, Rachmilewitz E . High incidence of cholelithiasis in older patients with homozygous beta-thalassemia. Acta Haematol. 1990; 83(3):120-2. DOI: 10.1159/000205186. View

5.
Jeney V, Balla J, Yachie A, Varga Z, Vercellotti G, Eaton J . Pro-oxidant and cytotoxic effects of circulating heme. Blood. 2002; 100(3):879-87. DOI: 10.1182/blood.v100.3.879. View